Sign up Australia
Proactive Investors - Run By Investors For Investors

Elixinol Global eyes new cannabis opportunities after raising $20 million

The company already manufactures and distributes hemp-based products in the U.S.
hemp food products
The company is now permitted to sell hemp food products in Australia

Elixinol Global Ltd (ASX:EXL) is the latest cannabis company to be admitted to the ASX and will commence trading from Monday, 8 January 2018.

The company has raised $20 million via an initial public offer of shares at $1.00 each.

Elixinol is already established in the U.S., where it manufactures and distributes industrial hemp-based nutraceuticals, dietary supplements and skincare products.

The company also owns Hemp Foods Australia, which was founded in 1999 and manufactures and distributes industrial hemp-derived products in Australia.

Elixinol’s strategy is to capitalise on the opportunities provided by being invested in a range of emerging cannabis related sectors including hemp, CBD (cannabidiol) nutraceuticals and wellness products.

New favourable cannabis regulation in Australia

Favourable legislative changes in Australia mean that Hemp Foods Australia is now permitted to sell hemp food products, offering the potential to expand distribution channels and grow its market.

In the medicinal cannabis sector, new legislation has been passed in Australia to enable the cultivation of cannabis for medicinal and related research purposes.

Earlier this week, the Australian federal government decided to allow export of medicinal cannabis in a bid to strengthen supply amid growing demand domestically and worldwide.

Elixinol US is an expert in CBD derived products

Subject to obtaining the requisite licences, Elixinol Australia can leverage Elixinol US’s expertise in extraction and processing of CBD derived products.

Each of the businesses within the Elixinol Group was co-founded by Paul Benhaim, a pioneer in the Australian industrial hemp sector.

Benhaim has over 25 years’ of experience in industrial hemp legislation, cultivation, manufacturing, production, sales and marketing in Europe, North America and Australasia.

View full EXL profile View Profile

Related Articles

test tubes
January 23 2018
Under former chief executive Peter George and his successor Shaun Chilton, it has been transformed via a series of well-judged, quickly integrated and, crucially, cash generative acquisitions
cancer cell
February 01 2018
The highlights included successful US and European ovarian cancer studies that underlined the potential of the company’s Parsortix liquid biopsy system
girl sneezing
February 13 2018
The Phase II study of its PQ Grass immunotherapy, an aluminium-free, ultra-short course hay fever treatment, is designed to evaluate dose response and safety

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use